Navigation Links
Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally
Date:1/14/2014

San Diego, CA (PRWEB) January 14, 2014

Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, today announced that they have entered into an international license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell conditioned media (CCM).

This agreement is an amendment to the existing license between Histogen and Suneva Medical, through which Suneva has exclusively licensed the Regenica® skincare line within the United States since February 2012. Under the terms of the international agreement, Suneva Medical is now the exclusive licensee for the distribution of Regenica through the physician-dispensed channel in Europe, most of Asia, South America, Canada, Australia, and the Middle East.

“Not only has Suneva had sales success, but they have generated enthusiasm around the Regenica product line and our technology here in the US,” said Gail K. Naughton, Ph.D., CEO and Chairman of the Board of Histogen. “We are excited about expanding our skincare partnership internationally, and look forward to an exciting year for Regenica.”

Regenica contains Histogen’s proprietary Multipotent Cell Conditioned Media, made up of soluble cell-signaing proteins and growth factors which support the body’s epidermal stem cells and renew skin throughout life. Through Histogen’s technology process, which mimics the embryonic environment including conditions of low oxygen and suspension, cells are triggered to become multipotent, and naturally produce these proteins associated with skin renewal and scarless healing.

“We believe that Regenica truly is the next generation in growth factor technology, and we are extremely pleased that the products will now have a presence around the world,” said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer of Suneva Medical. “Our relationship with Histogen in the US physician market has been a valuable asset to Suneva, and has laid the groundwork for international success.”

About Histogen

Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's lead product, Hair Stimulating Complex (HSC) has shown success in two Company-sponsored clinical trials as an injectable treatment for alopecia. In addition, the human multipotent cell conditioned media produced through Histogen's process can be found in skincare products including ReGenica, which is distributed by Suneva Medical in partnership with Obagi Medical Products. For more information, please visit http://www.histogen.com.

About Suneva Medical, Inc.

Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The company currently markets Artefill® in the US, Korea, Singapore and Vietnam; Refissa® and Regenica® Skincare in the U.S.; and Bellafill® in Canada. For more information, visit http://www.sunevamedical.com.

Regenica® is a trademark of Suneva Medical, Inc. The Multipotent Cell Conditioned Media Complex is covered by U.S. patents #8,257,947 and #8,524,494.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11486926.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen Creates PUR Biologics, a Joint Venture Developing Next-Generation, Biologic Solutions in Orthopedic Applications
2. Histogen Wins Appellate Court Hearing in SkinMedica Patent Case
3. Histogen’s Method of Generating Multipotent Stem Cells Receives US Patent
4. Histogen’s Composition for Hair Growth Receives US Patent
5. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
6. DiaTech Life Sciences Announces Medical Advisory Board
7. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
8. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
9. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
10. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
11. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
Breaking Biology Technology:
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
(Date:3/7/2017)... SALT LAKE CITY , March 7, 2017 /PRNewswire/ ... solutions that help top global companies identify the best ... Leonard as Chief Sales Officer (CSO) and ... and Kucer,s appointments round out a seasoned executive team poised ... year and beyond, building on a year of record ...
(Date:3/2/2017)... , March 2, 2017 Who risk ... lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
Breaking Biology News(10 mins):